With Bristol-Myers Squibb Co.'s $74bn acquisition of Celgene Corp. set to close in the third quarter – a deal that requires shareholder approval – Celgene spent its Jan. 31 earnings conference call reassuring investors that sales of its marketed drugs are growing and its pipeline programs remain on track.
In addition to Celgene's four blockbuster commercial products, Bristol highlighted five late-stage assets with US FDA approvals expected by 2020...








